Pharmaceuticals Latin America

Latin America Psychedelic Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Latin America Psychedelic Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Compound, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Latin America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $143.4 Mn Placeholder estimate
Estimate 2025 $163.3 Mn 4.3% of the global market
Projected 2034 $527.0 Mn 222.6% Adds $363.6 Mn over 9 forecast years
CAGR 2025–2034 13.9% Faster than 71% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Latin America is 4.26% of the global market.
  • Among regions, the largest is North America at $2.06 Bn.
  • Fastest growing: APAC at 14.4% a year.
  • Latin America ranks 4th of 6 by size among regions.

Market size projection

Latin America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$363.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Psychedelic Therapeutics Market market size by year, Latin America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $143.4 Mn — —
2025 (base) $163.3 Mn +$19.9 Mn —
2026 (forecast) $186.0 Mn +$22.7 Mn +13.9%
2027 (forecast) $211.9 Mn +$25.9 Mn +29.7%
2028 (forecast) $241.3 Mn +$29.5 Mn +47.8%
2029 (forecast) $274.9 Mn +$33.5 Mn +68.3%
2030 (forecast) $313.1 Mn +$38.2 Mn +91.7%
2031 (forecast) $356.6 Mn +$43.5 Mn +118.3%
2032 (forecast) $406.2 Mn +$49.6 Mn +148.7%
2033 (forecast) $462.7 Mn +$56.5 Mn +183.3%
2034 (forecast) $527.0 Mn +$64.3 Mn +222.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Latin America Psychedelic Therapeutics Market Analysis at a glance
Market size, 2025$163.3 Mn placeholder estimate
Forecast, 2034$527.0 Mn placeholder estimate
Growth (CAGR), 2025–203413.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsCompound, indication and end user (see all)
Key playersCompass Pathways, Lykos Therapeutics, MindMed, Cybin, atai Life Sciences (see all)
Active clinical trials2 in Latin AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Latin America Psychedelic Therapeutics Market Analysis Executive Summary

Psychedelic therapeutics use compounds such as psilocybin, MDMA and LSD with therapy support to treat depression, PTSD and addiction.

Key segments of the psychedelic Therapeutics market include compound (Psilocybin, MDMA and LSD) and indication (Treatment-Resistant Depression, PTSD and Substance Use Disorder).

Bar chart: Latin America Psychedelic Therapeutics market size, 2024–2034, placeholder estimates. $143.4 Mn in 2024, $163.3 Mn in 2025 and $527.0 Mn in 2034, 13.9% CAGR.
Latin America Psychedelic Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Latin America Psychedelic Therapeutics Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the psychedelic Therapeutics market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the psychedelic Therapeutics market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the psychedelic Therapeutics market.

Competitive Landscape for Psychedelic Therapeutics Market in Latin America

The psychedelic Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Psychedelic Therapeutics Market in Latin America

Psychedelic Therapeutics in Latin America: rules, payment and research

In some of the countries we cover here, medicines are approved by ANVISA (Brazil)⁠[1], ARCSA (Ecuador)⁠[2] and COFEPRIS (Mexico)⁠[3]. How care is paid for in some of these countries: the SUS (Brazil)⁠[4]; public care and IESS (Ecuador)⁠[5]; and IMSS, ISSSTE and IMSS-Bienestar (Mexico)⁠[6]. ClinicalTrials.gov lists 2 studies on Psychedelic Therapeutics that are recruiting, active or about to start in Latin America.⁠[7]

[1] ANVISA. Checked 14 Nov 2026.

[2] ARCSA. Checked 14 Nov 2026.

[3] COFEPRIS. Checked 14 Nov 2026.

[4] CONITEC. Checked 14 Nov 2026.

[5] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.

[6] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.

[7] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for psychedelic Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Latin America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Psychedelic Therapeutics right now, from free public sources.

Clinical trials

2 active trials in Brazil, Mexico, Ecuador and Haiti

Recruiting, about to start, or running now. Counted across the 4 countries we report on in Latin America.

Top trial sponsors (worldwide)

  1. Compass Pathways 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Psychedelic Therapeutics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Psychedelic Therapeutics market in Latin America?
Placeholder estimate: about $163.3 Mn in 2025, rising to about $527.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Psychedelic Therapeutics market in Latin America growing?
Placeholder estimate: about 13.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Psychedelic Therapeutics market report cover?
The report splits the market by compound (Psilocybin, MDMA, LSD, DMT and 5-MeO-DMT and more), indication (Treatment-Resistant Depression, PTSD, Substance Use Disorder, Anxiety) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Psychedelic Therapeutics market?
Key players include Compass Pathways, Lykos Therapeutics, MindMed, Cybin and atai Life Sciences.
What is driving the Psychedelic Therapeutics market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the psychedelic Therapeutics market. Governments and employers are investing more in mental health care.
How many clinical trials on Psychedelic Therapeutics are running in Latin America?
2 studies are recruiting, active or about to start in Latin America, counted across the 4 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
How much research is published on Psychedelic Therapeutics?
PubMed lists 30 papers on Psychedelic Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Latin America

See all

Related on mental health

See the topic